Summary
The IMPROVE-IT trial showed that the cholesterol-lowering drug ezetimibe, when added to simvastatin, provides greater improvement in cardiovascular outcomes among patients with diabetes vs those without diabetes in a population with acute coronary syndrome. Additionally, the rate of new-onset diabetes was not increased among patients treated with ezetimibe.
- acute coronary syndrome
- cardiovascular risk
- cholesterol
- diabetes mellitus
- ezetimibe
- IMPROVE-IT
- simvastatin
- © 2015 SAGE Publications